drugset / Trial / NCT05817162

Temporomandibular Joint Arthrocentesis With Infiltration of PRP + Ropivacaine Versus PRP

NCT05817162

Phase 4 Unknown 30 enrolled Instituto Portugues da Face
RandomizedParallel-groupSingle-blindTreatment

Summary

The infiltration of Platelet Rich Plasma (PRP) at the end of Temporomandibular Joint (TMJ) arthrocentesis is already an established procedure in the treatment of Temporomandibular Disorders (TMD). Arthrocentesis is a minimally invasive surgical procedure, which aims to eliminate the inflammatory mediators from the inside of the TMJ. PRP is an autologous concentrate of platelets and growth factors, derived from centrifugated blood. Several studies have described the benefits of PRP: it enhances wound healing because of the presence of cytokines and growth factors, and is also stimulates chondrocytes to biosynthesis of collagen. Ropivacaine is a local anesthetic that has been synthesized for use in infiltration anesthesia and to produce both peripheral and central block. Unlike one of its analogues, Bupivacaine, Ropivacaine anesthetize the sensory fibers without affecting the motor ones. The main goal of this investigation is to test the benefits of adding Ropivacaine to the infiltration of PRP in patients submitted to TMJ arthrocentesis.

Timeline

Start
2023-04-01
Primary completion
2024-04-01
Completion
2024-07-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ropivacaine Other / unclassified 7.5 mg/ml Other
Comparator Platelet Rich Plasma Other / unclassified 1 ml Other